Literature DB >> 15775753

Health implications of alpha1-antitrypsin deficiency in Sub-Sahara African countries and their emigrants in Europe and the New World.

Frederick J de Serres1, Ignacio Blanco, Enrique Fernández-Bustillo.   

Abstract

PURPOSE: To determine the frequencies of the protease inhibitor (PI) deficiency alleles of alpha1-antitrypsin deficiency (AAT Deficiency) in indigenous populations in 12 countries in Sub-Sahara Africa because of their potential impact on the health in these populations with regard to the high risk for development of liver and lung disease. In addition, to discuss the unique susceptibility of these populations and emigrants to Europe and the New World to the adverse health effects associated with exposure to environmental microbes, chemicals, and particulates.
METHODS: Detailed statistical analysis of the 24 control cohort databases from genetic epidemiological studies by others were used to estimate the allele frequencies and prevalence for the two most common deficiency alleles PIS and PIZ and to estimate the numbers at risk in each of the local Sub-Sahara populations as well as those who have emigrated from these countries to Europe and the New World.
RESULTS: The present study has provided evidence for the presence of both PIS and PIZ in the general populations of Nigeria, Republic of South Africa, and Somalia, the PIS allele in Angola, Botswana, Cameroon, Mozambique, Namibia, and the Republic of Congo, and only the PIZ allele in Mali.
CONCLUSION: AAT Deficiency is found in both the Black and "Colored" populations in many of the Sub-Sahara countries in Africa, providing evidence for the presence of AAT Deficiency in such populations in Europe and in the New World. Such populations should be screened for AAT Deficiency and made aware of their unique susceptibility to exposure to chemical and particulate agents in the environment.

Entities:  

Mesh:

Year:  2005        PMID: 15775753     DOI: 10.1097/01.gim.0000156533.06057.89

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  6 in total

1.  Alpha-1 Antitrypsin Deficiency PI*Z and PI*S Gene Frequency Distribution Using on Maps of the World by an Inverse Distance Weighting (IDW) Multivariate Interpolation Method.

Authors:  Ignacio Blanco; Frederick J de Serres; Victoriano Cárcaba; Beatríz Lara; Enrique Fernández-Bustillo
Journal:  Hepat Mon       Date:  2012-10-21       Impact factor: 0.660

2.  Alpha-1 antitrypsin Pi*SZ genotype: estimated prevalence and number of SZ subjects worldwide.

Authors:  Ignacio Blanco; Patricia Bueno; Isidro Diego; Sergio Pérez-Holanda; Beatriz Lara; Francisco Casas-Maldonado; Cristina Esquinas; Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-06-08

3.  Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update.

Authors:  Ignacio Blanco; Patricia Bueno; Isidro Diego; Sergio Pérez-Holanda; Francisco Casas-Maldonado; Cristina Esquinas; Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-02-13

4.  Case-finding for alpha1-antitrypsin deficiency in Kazakh patients with COPD.

Authors:  Angelo Corsico; Ilaria Ferrarotti; Ardak Zhumagaliyeva; Stefania Ottaviani; Timm Greulich; Marina Gorrini; Claus Vogelmeier; Ludmila Karazhanova; Gulmira Nurgazina; Annalisa DeSilvestri; Victor Kotke; Valentina Barzon; Michele Zorzetto
Journal:  Multidiscip Respir Med       Date:  2017-10-25

5.  Screening for Alpha 1 antitrypsin deficiency in Tunisian subjects with obstructive lung disease: a feasibility report.

Authors:  Sabri Denden; Michele Zorzetto; Fethi Amri; Jalel Knani; Stefania Ottaviani; Roberta Scabini; Marina Gorrini; Ilaria Ferrarotti; Ilaria Campo; Jemni Ben Chibani; Amel Haj Khelil; Maurizio Luisetti
Journal:  Orphanet J Rare Dis       Date:  2009-04-15       Impact factor: 4.123

6.  Case finding of Alpha-1 antitrypsin deficiency: never wasted time!

Authors:  Bruno Balbi
Journal:  Multidiscip Respir Med       Date:  2018-01-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.